View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Research Reports
May 26, 2017

Burden of Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) are a common and disabling condition among people with diabetes.

Diabetic foot ulcers (DFU) are a common and disabling condition among people with diabetes. The lifetime risk of an individual with diabetes developing a DFU is approximately 25%.

DFU has become an increasingly significant public health concern in both the developed and the developing world. They are a major cause of hospitalisations and the leading cause of limb amputations in diabetics.

GlobalData epidemiologists have forecast that the diagnosed incident cases of DFU among the diabetic population in seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan will increase from 1,060,036 cases in 2015 to 1,487,754 cases in 2025, at an annual growth rate (CAGR) of 4.03%.

The US is expected to have the highest number of diagnosed incident cases of DFU (534,724 in 2015 to 793,659 in 2025) among the 7MM throughout the forecast period.

Figure 1 presents the expected changes in the 7MM from 2015 to 2025.

Within the 7MM, the US accounted for 50.44% of the diagnosed incident cases in 2015, whereas the five EU countries combined (the UK, France, Germany, Italy, and Spain) had 36.99% of diagnosed incident cases. GlobalData epidemiologists estimate that the diagnosed incident cases of DFU will grow by 40.35% over the forecast period.

Adults aged 60–69 years and 50–59 years composed the highest proportion of diagnosed incident cases of DFU, accounting for approximately 50% of the population. Ages 20–29 years accounted for the fewest diagnosed cases. This suggests that people are more likely to develop a DFU as they age.

DFUs decrease the quality of life and are costly to treat. As the population is ageing and there is an increasing prevalence of diabetes, GlobalData epidemiologists expect complications related to this condition are also likely to increase over the next 20 years. Therefore, it is expected that diabetes, DFU, and other associated infections will continue to burden healthcare systems and require the greater allocation of healthcare resources in the 7MM.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena